News >

Optimizing Immunotherapy Remains a Challenge in NSCLC

Danielle Bucco
Published: Tuesday, Aug 29, 2017

David R. Gandara, MD

David R. Gandara, MD
Immunotherapy is rapidly altering the treatment landscape in non–small cell lung cancer (NSCLC), but many questions still remain, according to David R. Gandara, MD.

, Gandara, director of the Thoracic Oncology Program, professor at UC Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care in Lung Cancer, discussed the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.

OncLive: What is your reaction to the MYSTIC trial findings?

Gandara: The results of the MYSTIC trial have been much anticipated. This is a phase III trial in advanced-stage NSCLC, randomizing patients to standard-of-care platinum chemotherapy versus either durvalumab (Imfinzi) alone or durvalumab plus tremelimumab, a CTLA-4 inhibitor. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Publication Bottom Border
Border Publication